Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Michael Tuttle

Showing results (141-150 of 320) with videos related to

Pageof 32
Sort By:
Human Pathology|February 28, 2015
Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variantIan Ganly, Laura Wang, R Michael Tuttle, et al.
Thyroid : Official Journal of the American Thyroid Association|May 13, 2015
Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to HealthcareJennifer L Marti, Louise Davies, Megan R Haymart, et al.
Thyroid : Official Journal of the American Thyroid Association|March 2, 2010
Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy functionR Michael Tuttle, Norma Lopez, Rebecca Leboeuf, et al.
European Endocrinology|April 11, 2018
Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive IodineShrujal S Baxi, Rachel Kurtzman, Anne Eaton, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|July 26, 2003
Tumor size and extent of disease at diagnosis predict the response to initial therapy for papillary thyroid carcinoma in children and adolescentsPatricia A Powers, Catherine A Dinauer, R Michael Tuttle, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2006
Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancerR Michael Tuttle, Rebecca Leboeuf, Richard J Robbins, et al.
The Journal of Clinical Endocrinology and Metabolism|March 30, 2016
Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive IodineDenise P Momesso, Fernanda Vaisman, Samantha P Yang, et al.
Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine|May 26, 2017
Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin UnnecessaryJosé M Domínguez, Flavia Nilo, Tania Contreras, et al.
Annals of Clinical and Laboratory Science|June 24, 2003
Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse modelAndrew J Bauer, Aneeta Patel, Richard Terrell, et al.
Histopathology|April 27, 2022
The solid variant of papillary thyroid carcinoma: a multi-institutional retrospective studyBin Xu, Kartik Viswanathan, Lingxin Zhang, et al.
Pageof 32

Showing results (141-150 of 320) with videos related to

Sort By:
Pageof 32
Human Pathology|February 28, 2015
Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variantIan Ganly, Laura Wang, R Michael Tuttle, et al.
Thyroid : Official Journal of the American Thyroid Association|May 13, 2015
Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to HealthcareJennifer L Marti, Louise Davies, Megan R Haymart, et al.
Thyroid : Official Journal of the American Thyroid Association|March 2, 2010
Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy functionR Michael Tuttle, Norma Lopez, Rebecca Leboeuf, et al.
European Endocrinology|April 11, 2018
Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive IodineShrujal S Baxi, Rachel Kurtzman, Anne Eaton, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|July 26, 2003
Tumor size and extent of disease at diagnosis predict the response to initial therapy for papillary thyroid carcinoma in children and adolescentsPatricia A Powers, Catherine A Dinauer, R Michael Tuttle, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2006
Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancerR Michael Tuttle, Rebecca Leboeuf, Richard J Robbins, et al.
The Journal of Clinical Endocrinology and Metabolism|March 30, 2016
Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive IodineDenise P Momesso, Fernanda Vaisman, Samantha P Yang, et al.
Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine|May 26, 2017
Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin UnnecessaryJosé M Domínguez, Flavia Nilo, Tania Contreras, et al.
Annals of Clinical and Laboratory Science|June 24, 2003
Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse modelAndrew J Bauer, Aneeta Patel, Richard Terrell, et al.
Histopathology|April 27, 2022
The solid variant of papillary thyroid carcinoma: a multi-institutional retrospective studyBin Xu, Kartik Viswanathan, Lingxin Zhang, et al.
Pageof 32